title: Apoptotic versus autophagic cell death in heart failure.
abstract: OBJECTIVE
  Progressive loss of cardiomyocytes is one of the most important pathogenic characteristics of heart failure. Apoptosis may be an important mode of cell death in heart failure but it must be demonstrated by multiple criteria and not just TUNEL staining alone. Previously, we and others have demonstrated that besides apoptosis other phenomena like active gene transcription can result in TUNEL positivity. Moreover, other types of cell death that are caspase-independent could be important in heart failure. This study examined the hypothesis whether TUNEL labeling parallels caspase activation.
  
  
  METHODS
  Cardiac tissue of patients in the terminal stage of heart failure as a consequence of ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) were studied. Embryonic mice hearts were used for positive control for detection of the classical apoptosis.
  
  
  RESULTS
  In mice embryonic hearts we could clearly find apoptotic cell death detected by TUNEL labeling and immunohistochemistry for activated caspase-3. In heart failure, TUNEL-positive cardiomyocytes were negative for active caspase-3 but showed signs of active gene transcription (SC-35). However, autophagic cell death could be found in 0.3% of the cardiomyocytes. Autophagic cell death was demonstrated by granular cytoplasmic ubiquitin inclusions, an established marker of autophagocytosis in neurons. Interestingly, these autophagic cardiomyocytes were TUNEL and activated caspase-3 negative but were also negative for C9, a marker for necrosis. Western blot analysis confirmed that in cardiomyopathies no cleavage of caspase-3 and caspase-7 occurred.
  
  
  CONCLUSIONS
  The present study demonstrates two fundamentally different situations of cell death in cardiac tissue. In embryonic mice, cardiomyocytes undergo caspase-dependent cell death. However, cardiomyocytes in heart failure show caspase-independent autophagic cell death rather than apoptotic cell death.
authors.affiliation: HistoGeneX (Histological Gene Expression Systems), Antwerp, Belgium.
authors.forename: M W
authors.initials: MW
authors.lastname: Knaapen
authors.forename: M J
authors.initials: MJ
authors.lastname: Davies
authors.forename: M
authors.initials: M
authors.lastname: De Bie
authors.forename: A J
authors.initials: AJ
authors.lastname: Haven
authors.forename: W
authors.initials: W
authors.lastname: Martinet
authors.forename: M M
authors.initials: MM
authors.lastname: Kockx
mesh_terms: D000818:Animals; D017209:Apoptosis; D002311:Cardiomyopathy, Dilated / Q000201:enzymology / Q000473:pathology*; D016022:Case-Control Studies; D020169:Caspases / Q000378:metabolism; D016923:Cell Death; D053938:DNA Fragmentation; D004789:Enzyme Activation; D005318:Fetal Heart / Q000201:enzymology / Q000473:pathology; D006801:Humans; D020287:In Situ Nick-End Labeling; D051379:Mice; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000201:enzymology / Q000473:pathology*; D009206:Myocardium / Q000201:enzymology / Q000473:pathology*; D012342:RNA, Small Nuclear / Q000378:metabolism
chemical_list: D012342:RNA, Small Nuclear; D020169:Caspases